Copeptin and Nonalcoholic Fatty Liver Disease
Determine if copeptin levels, a marker of vasopressin, correlates with presence and severity of fatty liver disease.
Why this Research Matters
See above
Who can Participate
Adult
Obese 30-40 BMI, age 30-75 Diabetes, other liver disease or eGFR<45.
Study ID
Protocol Number: 17-1160
More information available at ClinicalTrials.gov: NCT03254563
Meet the Team
Principal Investigator
Locations
-
UCD Anschutz Health & Wellness Center
University of Colorado Hospital
- Anschutz Health and Wellness
- Outpatient CTRC